Michael is the Co-Founder of ReCode Therapeutics; an LNP delivery platform company spun out of UT-Southwestern Medical Center. Michael transitioned an academic project into a VC-backed company, raising $280M over two years from a syndicate of top-tier healthcare funds that includes Orbimed, MPM Capital, Colt Ventures, and Vida Ventures, among others. Michael was VP of R&D and Texas site head, overseeing the planning, budgeting, and project management of 3 therapeutic programs and several discovery projects. Additionally, he is a business development expert with a deep network of buy-side and sell-side contacts.

Michael earned his bachelor’s degree in Biology from Dallas Baptist University in 2006. While at DBU, he was selected as a National Institute of Health UGSP Scholar and spent a year performing research at the National Cancer Institute before entering a Ph.D. program. Michael earned his Ph.D. in cancer biology from UT-Southwestern Medical Center.